IRF8 and osteosarcoma: In the present study, we demonstrate that PD-L1 induced by ICSBP promotes osteosarcoma growth and tumorigenicity and that PD-L1 knockdown combined with doxorubicin treatment synergistically inhibits osteosarcoma growth, both in vitro and in vivo.